Je was op zoek naar: rrapurtat (Maltees - Engels)

ma ġie rrapurtat l-ebda suspett avvers.
no safety concerns were raised.

l-ebda każ ta’ doża eċċessiva ma ġie rrapurtat.
no case of overdose has been reported.

l-ebda każ ta’ doża eċċessiva b’depocyte ma ġie rrapurtat.
no overdoses with depocyte have been reported.

il-prezz medju għandu jiġi rrapurtat bir-rati nazzjonali għal kull tunellata.
the average price is to be reported in national currency per tonne.

l-ebda każ ta’ doża eċċessiva ta’ starlix ma ġie rrapurtat fi studji kliniċi.
there is no experience of an overdose of starlix in clinical trials.

l- ebda sintomu ta 'doża eċċessiva bil- fattur viii rikombinanti għal koagulazzjoni ma ġie rrapurtat.
no symptoms of overdosage with recombinant coagulation factor viii have been reported.

xi disturbi newroloġiku li deher iktar tard ġie rrapurtat (ipertonja, aċċessjoni, imġieba mhux normali).
some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour).

l-ebda każ ta’ doża eċċessiva ma ġie rrapurtat, u dan mhux mistenni li jseħħ wara li jingħata fl-għajn.
no case of overdose has been reported, and is unlikely to occur after ocular administration.

f'dak li hu marbut mat-talbiet ta' verifika, l-olanda rrapurtat tmien każijiet minn sitt stati membri.
the netherlands reported eight requests for verification by six member states.

ipertirojdiżmu ġie rrapurtat f’ 4 (1.7%) pazjenti b’ sunitinib u fl-ebda pazjent b’capecitabine.
hyperthyroidism was reported in 4 (1.7%) sunitinib subjects and no capecitabine subjects.

dan ir-rapport huwa msejjes fuq il-ħidma tas-sottogrupp, kif ġie rrapurtat fil-laqgħa plenarja ta' marzu 2009.
this report is based on the work of the sub-group as reported to the plenary meeting of march 2009.

minkejja l-eżistenza tad-direttiva, huwa biss terz mill-iskart elettriku u elettroniku fil-komunità li jiġi rrapurtat bħala trattat kif suppost.
despite the existence of the directive, only one third of electrical and electronic waste in the community is reported as appropriately treated.

Ġie rrapurtat raxx qawwi marbut ma’ nfafet, tqaxxir umdu tal-ġilda u ulċeri f’inqas minn 1% mill-pazjenti kkurati b’efavirenz.
severe rash associated with blistering, moist desquamation or ulceration has been reported in less than 1% of patients treated with efavirenz.